MED12L

Across TCGA pan-cancer cohorts, MED12L RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated MED12L data layer compared with 9 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MED12L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED12L expression acts as an unfavorable survival marker, although some lineages such as BRCA and SCLC show a favorable association.

BLCA, BRCA, and SCLC are the cancer types where MED12L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Quartile	II,III,IV	0.540	0.730	.002	77	view →
BRCA	DFS	Median	III,IV	0.878	0.705	<.001	56	view →
SCLC	DFS	Quartile	II,III,IV	0.793	0.316	<.001	50	view →
STAD	DFS	Tertile	All	0.560	0.721	.002	47	view →
SKCM	OS	Tertile	All	0.411	0.262	<.001	45	view →
PAAD	DFS	Median	All	0.430	0.290	.004	41	view →
LUSC	OS	Tertile	All	0.469	0.284	<.001	36	view →
UCEC	DFS	Tertile	All	0.765	0.883	<.001	36	view →
UVM	DFS	Quartile	III,IV	0.239	0.844	.004	36	view →
ACC	DFS	Tertile	All	0.487	0.779	.003	33	view →
COAD	DFS	Median	II,III,IV	0.683	0.808	.001	24	view →
UCS	OS	Quartile	II,III,IV	0.658	0.255	.018	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

MED12L–BLCA (DFS)

Open the BLCA breakdown →